The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats

Brain Research

Volumn 909, Issue 1-2, 2001, Pages 75-80

  Jewett, David C ^a,c   Grace, Martha K ^d   Jones, Robert M ^b   Billington, Charles J ^c,d,e   Portoghese, Phillip S ^b   Levine, Allen S ^c,d,e  

^a UNIVERSITY OF WISCONSIN EAU CLAIRE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d VA MEDICAL CENTER   (United States)

^e University of Minnesota   (United States)

Author keywords

Eating; Feeding; GNTI; Kappa opioid; Rat

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 5' GUANIDINOLNALTRINDOLE; ANOREXIGENIC AGENT; APPETITE STIMULANT; BUTORPHANOL; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NEUROPEPTIDE Y; NORBINALTORPHIMINE; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; FEEDING; FOOD DEPRIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BRAIN; BUTORPHANOL; DRUG INTERACTIONS; EATING; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; FOOD DEPRIVATION; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEUROPEPTIDE Y; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA;

EID: 0035800635     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)02624-5     Document Type: Article

References (21)

1. Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphamine
2. Opioid receptor sybtype antagonists and ingestion
3. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on K-opioid agonists in the mouse writing assay
4. Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys
5. Nor-binaltorphimine (nor-BNI): A potent and selective kappa-opioid receptor antagonist with ultra-long lasting activity in vivo
6. Stimulation of ingestive behaviour by preferential and selective opioid agonists
7. The stimulation of food intake by selective agonists of mu, kappa and delta opioid receptors
8. Extremely long-lasting antagonist actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test
9. Effects of neuropeptide Y, insulin, 2-deoxyglucose, and food deprivation on food-motivated behavior
10. Duration of the anorectic action of norbinaltorphimine on neuropeptide-Y induced feeding in rats
11. Nor-binaltorphimine: An ultra-long acting kappa-opioid antagonist in pigeons
12. Mutational evidence for a common K antagonist binding pocket in the wild-type K and mutant μ[K303E] opioid receptors
13. The effect of norbinaltorphimine, β-funaltrexamine and naltrindole on NPY-induced feeding
14. Nor-binaltorphimine decreases deprivation and opioid-induced feeding
15. The effect of selective opioid antagonists on butorphanol-induced feeding
16. Neuropeptide Y: A potent inducer of consummatory behavior in rats
17. Opioids and rate of positively reinforced behavior. III. Antagonism by the long-lasting kappa antagonist norbinaltorphimine
18. 1, stimulates feeding in rats
19. Butorphanol increases food-reinforced operant responding in satiated rats
20. Effects of β-funaltrexamine on ingestive behaviors in the rat
21. 5′-Guanidinolnaltrindole, a highly selective and potent kappa-opioid receptor antagonist